There may be a more appropriate test, please see: Fragile X Syndrome (FXS), Fragile X (associated) Tremor/Ataxia Syndrome (FXTAS)
Premature ovarian insufficiency is a heterogeneous disorder characterised by menopause before the age of 40 years. Up to 20% of female carriers of a Premutation in the FMR1 gene at Xq27.1 develop premature ovarian insufficiency, and this form of the condition has been classified as Fragile X Associated Primary Ovarian Insufficiency (FXPOI). The relationship between the premutation size and the risk of developing FXPOI is not linear, with maximum risk confined to carriers with an expansion of 80-100 CGG repeats (Ennis et al 2006). The molecular basis of FXPOI is unknown.
Testing is used for confirmation of a clinical diagnosis of FXPOI or for exclusion of the diagnosis in patients with relevant clinical indications. Within families with a history of FXPOI, testing is used to confirm a diagnosis or to establish or exclude carrier status following appropriate genetic counselling.
Size analysis of the (CGG)n repeat region of the FMR1 gene is undertaken using PCR based technologies (Standard FMR1 PCR and/or AmplideX™ FMR1 PCR) see test validation details below.
Price & reporting times
NHS referrals to this service are paid for where there is an existing specialist commissioning contract for genetic testing. In other cases please contact the lab for prices.
Price (non- NHS)
|TRT (Calendar days)|
|Standard FMR1 PCR test/ AmplideX™ FMR1 PCR test||POA||POA||28|
Test validation & quality assurance - information for users
The Standard FMR1 PCR test is used to detect “Normal” and “Intermediate” and some of the smaller “Premutation” alleles of the FMR1 CGG triplet repeat region. Larger “Premutation” and “Full Mutation” expansions cannot be detected with this method, and it is therefore used only as an “exclusion” test. If the Standard FMR1 PCR test results are inconclusive, the AmplideX™ FMR1 PCR test is performed (using a commercial kit, www.asuragen.com). This enables the detection of FMR1 repeat alleles up to and including full mutations (>200 repeats). Sizing accuracy for both tests is estimated to be +/-2 repeats for alleles in the Normal, Intermediate and Premutation ranges. The FMR1 PCR analysis has a sensitivity and specificity of >98%. The testing is therefore effective for exclusion of FXPOI as a likely diagnosis.
4ml EDTA blood sample
Please see our referral guidelines for more information.
OMIM Number(s) - 311360
Gene(s) - FMR1